Figure 5.

HMBD-002 remodels the immune milieu toward a proinflammatory Th1 immune response in an allogenic mixed lymphocyte reaction (MLR). (A) Cytokine levels measured at 96 hours by Luminex, from the supernatant of an allogenic mixed lymphocyte reaction. All concentrations of HMBD-002 and anti PD-1 antibody, pembrolizumab (annotated as pembro) in μg/ml. Data were normalized to isotype control. Data shown are mean of n=10 and error bars are SEM. P values were obtained by unpaired t-test, *p<0.05, **p<0.01. (B) Speed2 pathway analysis from bulk RNA-sequencing of MLR samples (n=10). Data were normalized to isotype control, represented as mean ± SD and the p adjusted values were obtained from bulk RNA sequencing analysis, **p<0.01, ***p<0.001. IFN, interferon; IL, interleukin; PD-1, programmed cell death protein-1; TNF, tumor necrosis factor.